INmune Bio, Inc.
INMB
$7.32
$0.010.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -90.97% | -81.25% | -69.53% | -47.39% | -58.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.97% | -81.25% | -69.53% | -47.39% | -58.56% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -90.97% | -81.25% | -69.53% | -47.39% | -58.56% |
| SG&A Expenses | -1.45% | 2.27% | 8.43% | 4.10% | 3.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.66% | 52.74% | 44.57% | 31.83% | 13.57% |
| Operating Income | -43.35% | -53.85% | -45.80% | -32.59% | -14.60% |
| Income Before Tax | -40.24% | -50.45% | -41.91% | -28.09% | -9.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.24% | -50.45% | -41.91% | -28.09% | -9.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.24% | -50.45% | -41.91% | -28.09% | -9.92% |
| EBIT | -43.35% | -53.85% | -45.80% | -32.59% | -14.60% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -27.65% | -42.89% | -38.89% | -27.67% | -9.57% |
| Normalized Basic EPS | -27.66% | -42.91% | -38.93% | -27.69% | -9.58% |
| EPS Diluted | -27.65% | -42.89% | -38.89% | -27.67% | -9.57% |
| Normalized Diluted EPS | -27.66% | -42.91% | -38.93% | -27.69% | -9.58% |
| Average Basic Shares Outstanding | 10.91% | 5.14% | 2.20% | 0.30% | 0.30% |
| Average Diluted Shares Outstanding | 10.91% | 5.14% | 2.20% | 0.30% | 0.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |